Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

View Full Paper
Ask AI
Bookmark
Share

Authors

SHShahrier HossainASAdam S. SperlingBFBrendan Fink

Discussion

Loading...

Member takes

Overview

Open-label trial shows elranatamab achieves 100% overall response in relapsed AL amyloidosis, highlighting its potential efficacy.

Key Points

  • This interim report aims to evaluate the safety and efficacy of elranatamab in patients with relapsed AL amyloidosis.
  • Phase I/II, open-label, single-arm clinical trial.
  • Included adult patients with relapsed AL amyloidosis after prior therapies.
  • Patients received elranatamab in step-up doses followed by weekly maintenance doses.
  • At 5.5 months follow-up, 100% overall response rate (ORR) was observed.
  • 100% achieved ≥ very good partial response and 60% achieved complete responses.
  • Cytokine release syndrome occurred in 4 patients, with no new safety signals reported.

Cite This Study

Hossain et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de30https://doi.org/10.1182/blood-2025-5808
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Preliminary results from the prospective, non-interventional MagnetisMM-16 study.2026
  2. 2Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM‐32026
  3. 3Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma2025 · 8 citations
  4. 4Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.2026
  5. 5Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium2026 · 6 citations